Surmont VF - Search Results

1

Malignant pleural mesothelioma: the standard of care and challenges for future management.

van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P. van Meerbeeck JP, et al. Among authors: surmont vf. Crit Rev Oncol Hematol. 2011 May;78(2):92-111. doi: 10.1016/j.critrevonc.2010.04.004. Epub 2010 May 13. Crit Rev Oncol Hematol. 2011. PMID: 20466560 Review.

2

Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma.

Raman L, Van der Linden M, Van der Eecken K, Vermaelen K, Demedts I, Surmont V, Himpe U, Dedeurwaerdere F, Ferdinande L, Lievens Y, Claes K, Menten B, Van Dorpe J. Raman L, et al. Genome Med. 2020 Apr 21;12(1):35. doi: 10.1186/s13073-020-00735-4. Genome Med. 2020. PMID: 32317009 Free PMC article.

3

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.

Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Wu YL, et al. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. N Engl J Med. 2020. PMID: 32955177 Clinical Trial.

4

Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study.

Cuppens K, Lodewyckx L, Demedts I, Decoster L, Colinet B, Deschepper K, Janssens A, Galdermans D, Pieters T; REVEAL Study Group. Cuppens K, et al. Drugs Real World Outcomes. 2021 Jun;8(2):141-152. doi: 10.1007/s40801-021-00243-w. Epub 2021 Mar 12. Drugs Real World Outcomes. 2021. PMID: 33710523 Free PMC article.

5

Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.

van den Bogaert DP, Pouw EM, van Wijhe G, Vernhout RM, Surmont VF, Hoogsteden HC, van Klaveren RJ. van den Bogaert DP, et al. Among authors: surmont vf. J Thorac Oncol. 2006 Jan;1(1):25-30. J Thorac Oncol. 2006. PMID: 17409823 Clinical Trial.

6

Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developments.

van Meerbeeck JP, Surmont VF. van Meerbeeck JP, et al. Among authors: surmont vf. Lung Cancer. 2009 Sep;65(3):257-67. doi: 10.1016/j.lungcan.2009.02.007. Epub 2009 Mar 13. Lung Cancer. 2009. PMID: 19285751 Review.

7

What is the role for surgery in patients with stage III non-small cell lung cancer?

Vandenbroucke E, De Ryck F, Surmont V, van Meerbeeck JP. Vandenbroucke E, et al. Curr Opin Pulm Med. 2009 Jul;15(4):295-302. doi: 10.1097/MCP.0b013e32832cbefc. Curr Opin Pulm Med. 2009. PMID: 19465855 Review.

8

Adjuvant or neoadjuvant chemotherapy in minimal N2 stage IIIA nonsmall cell lung cancer.

De Craene S, Surmont V, van Meerbeeck JP. De Craene S, et al. Curr Opin Oncol. 2010 Mar;22(2):102-11. doi: 10.1097/cco.0b013e328335c076. Curr Opin Oncol. 2010. PMID: 20180283

9

Malignant pleural mesothelioma: when is radiation therapy indicated?

van Thiel ER, Surmont VF, van Meerbeeck JP. van Thiel ER, et al. Among authors: surmont vf. Expert Rev Anticancer Ther. 2011 Apr;11(4):551-60. doi: 10.1586/era.10.169. Expert Rev Anticancer Ther. 2011. PMID: 21504322 Review.

10

Raltitrexed in mesothelioma.

Surmont VF, van Meerbeeck JP. Surmont VF, et al. Expert Rev Anticancer Ther. 2011 Oct;11(10):1481-90. doi: 10.1586/era.11.136. Expert Rev Anticancer Ther. 2011. PMID: 21999120 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results